Cusatuzumab ELISA Kit

Cusatuzumab is designed as a first-in-class, high-affinity anti-CD70 monoclonal antibody with multiple intended mechanisms of action, including Fc-mediated cytotoxicity with enhanced ADCC and inhibition of CD70/CD27 signaling, resulting in killing of malignant cells such as leukemia blasts and stem cells.

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.